HONG KONG, Feb. 1, 2018 /PRNewswire/ — Golden Meditech Holdings Limited (SEHK stock code: 00801) (the "Company"), a leading integrated healthcare enterprise in China, announces today the TDR repurchase period is closed on January 31, 2018, regarding the proposed voluntary delisting of the Taiwan depository receipts ("TDR") from the Taiwan Stock Exchange Corporation. The Company is obliged to repurchase approximately 49.21 million outstanding TDRs at a total consideration of approximately NT$219 million (approximately HK$58.71 million).
Details have been published by the Company in accordance with the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited and posted on the Company’s website as follows: http://www.goldenmeditech.com/eng/ir/announcements.php?year=2018
About Golden Meditech Holdings Limited (SEHK stock code: 00801)
Golden Meditech (www.goldenmeditech.com) is a leading integrated-healthcare enterprise in China. It is a first-mover in China, having established its dominant positions in several markets including the medical devices market and the hospital management market in the healthcare industry, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, Golden Meditech will continue to pursue a leading position in China’s healthcare industry both through organic growth and strategic expansion.